Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyEquilin
Identification
- Name
- Equilin
- Accession Number
- DB02187 (EXPT01355)
- Type
- Small Molecule
- Groups
- Approved
- Description
An estrogenic steroid produced by horses. It has a total of four double bonds in the A- and B-ring. High concentration of euilin is found in the urine of pregnant mares. [PubChem]
Equilin is one of the estrogens present in the mixture of estrogens isolated from horse urine and marketed as Premarin. Premarin became the most commonly used form of estrogen for hormone replacement therapy in the United States of America. Estrone is the major estrogen in Premarin (about 50%) and equilin is present as about 25% of the total. Estrone is a major estrogen that is normally found in women. Equilin is not normally present in women, so there has been interest in the effects of equilin on the human body. [Wikipedia]
The estrogens in Premarin are present mainly as "conjugates", modified chemical forms in which the active estrogen is coupled to another chemical group such as sulfate. Estrone sulfate is usually the major form of estrogen in women. After being taken into a woman's body, the conjugated estrogens of Premarin are converted to the active unconjugated estrogens or excreted from the woman's body. Estrone can be converted to estradiol, which is thought to be the major active estrogen in women. [Wikipedia]
- Structure
Structure for DB02187 (Equilin)
- Synonyms
- 1,3,5,7-Estratetraen-3-ol-17-one
- 7-Dehydroestrone
- Dihydroequilenin
- Equilin
- Categories
- UNII
- 08O86EX0J4
- CAS number
- 474-86-2
- Weight
- Average: 268.3502
Monoisotopic: 268.146329884 - Chemical Formula
- C18H20O2
- InChI Key
- WKRLQDKEXYKHJB-HFTRVMKXSA-N
- InChI
- InChI=1S/C18H20O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3-5,10,14,16,19H,2,6-9H2,1H3/t14-,16+,18+/m1/s1
- IUPAC Name
- (1S,11S,15S)-5-hydroxy-15-methyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-2(7),3,5,9-tetraen-14-one
- SMILES
- [H][[email protected]@]12CCC(=O)[[email protected]@]1(C)CC[[email protected]]1([H])C3=C(CC=C21)C=C(O)C=C3
Pharmacology
- Indication
For the treatment of moderate to severe vasomotor symptoms associated with the menopause, atrophic vaginitis, osteoporosis, hypoestrogenism due to hypogonadism, castration, primary ovarian failure, breast cancer (for palliation only), and Advanced androgen-dependent carcinoma of the prostate (for palliation only)
- Structured Indications
- Not Available
- Pharmacodynamics
Equilin is a component of Premarin (conjugated estrogens), a mixture of the water soluble salts of sulfate esters from estrone, equilin, 17 alpha-dihydroequilin, and other related steroids, may be derived from pregnant equine urine or yam and soy plants. Estrogens are important in the development and maintenance of the female reproductive system and secondary sex characteristics. They promote growth and development of the vagina, uterus, and fallopian tubes, and enlargement of the breasts. Indirectly, they contribute to the shaping of the skeleton, maintenance of tone and elasticity of urogenital structures, changes in the epiphyses of the long bones that allow for the pubertal growth spurt and its termination, growth of axillary and pubic hair, and pigmentation of the nipples and genitals. Decline of estrogenic activity at the end of the menstrual cycle can bring on menstruation, although the cessation of progesterone secretion is the most important factor in the mature ovulatory cycle. However, in the preovulatory or nonovulatory cycle, estrogen is the primary determinant in the onset of menstruation. Estrogens also affect the release of pituitary gonadotropins. The pharmacologic effects of conjugated estrogens are similar to those of endogenous estrogens.
- Mechanism of action
Estrogens enter the cells of responsive tissues (e.g., female organs, breasts, hypothalamus, pituitary) where they interact with a protein receptor, subsequently increasing the rate of synthesis of DNA, RNA, and some proteins. Estrogens decrease the secretion of gonadotropin-releasing hormone by the hypothalamus, reducing the secretion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the pituitary.
Target Actions Organism UEstradiol 17-beta-dehydrogenase 1 Not Available Human UEstrogen receptor alpha Not Available Human - Absorption
Well absorbed.
- Volume of distribution
- Not Available
- Protein binding
90% bound to plasma proteins
- Metabolism
Hepatic
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 1,10-Phenanthroline The risk or severity of adverse effects can be increased when Equilin is combined with 1,10-Phenanthroline. Experimental Aceclofenac The risk or severity of adverse effects can be increased when Aceclofenac is combined with Equilin. Approved Acemetacin The risk or severity of adverse effects can be increased when Acemetacin is combined with Equilin. Approved Acetylsalicylic acid The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Equilin. Approved, Vet Approved Adapalene The risk or severity of adverse effects can be increased when Adapalene is combined with Equilin. Approved Alclofenac The risk or severity of adverse effects can be increased when Alclofenac is combined with Equilin. Approved, Withdrawn Aldesleukin Equilin may decrease the antineoplastic activities of Aldesleukin. Approved Algeldrate The bioavailability of Equilin can be decreased when combined with Algeldrate. Experimental Almagate The bioavailability of Equilin can be decreased when combined with Almagate. Experimental Almasilate The bioavailability of Equilin can be decreased when combined with Almasilate. Experimental Alminoprofen The risk or severity of adverse effects can be increased when Alminoprofen is combined with Equilin. Experimental Aloglutamol The bioavailability of Equilin can be decreased when combined with Aloglutamol. Experimental Aloxiprin The risk or severity of adverse effects can be increased when Aloxiprin is combined with Equilin. Experimental Aluminium The bioavailability of Equilin can be decreased when combined with Aluminium. Approved Aluminium acetoacetate The bioavailability of Equilin can be decreased when combined with Aluminium acetoacetate. Experimental Aluminium glycinate The bioavailability of Equilin can be decreased when combined with Aluminium glycinate. Experimental Aluminum hydroxide The bioavailability of Equilin can be decreased when combined with Aluminum hydroxide. Approved Ambenonium The risk or severity of adverse effects can be increased when Equilin is combined with Ambenonium. Approved Aminosalicylic Acid The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Equilin. Approved Amiodarone The serum concentration of Equilin can be increased when it is combined with Amiodarone. Approved, Investigational Amphotericin B Equilin may increase the hypokalemic activities of Amphotericin B. Approved, Investigational Andrographolide The risk or severity of adverse effects can be increased when Andrographolide is combined with Equilin. Investigational Anisodamine The risk or severity of adverse effects can be increased when Anisodamine is combined with Equilin. Investigational Antipyrine The risk or severity of adverse effects can be increased when Antipyrine is combined with Equilin. Approved Apocynin The risk or severity of adverse effects can be increased when Apocynin is combined with Equilin. Investigational Apremilast The risk or severity of adverse effects can be increased when Apremilast is combined with Equilin. Approved, Investigational Aprepitant The serum concentration of Equilin can be increased when it is combined with Aprepitant. Approved, Investigational Atazanavir The serum concentration of Equilin can be increased when it is combined with Atazanavir. Approved, Investigational Atracurium besylate Atracurium besylate may increase the adverse neuromuscular activities of Equilin. Approved Azapropazone The risk or severity of adverse effects can be increased when Azapropazone is combined with Equilin. Withdrawn Azelastine The risk or severity of adverse effects can be increased when Azelastine is combined with Equilin. Approved Balsalazide The risk or severity of adverse effects can be increased when Balsalazide is combined with Equilin. Approved, Investigational BCG vaccine The risk or severity of adverse effects can be increased when Equilin is combined with BCG vaccine. Investigational Bendazac The risk or severity of adverse effects can be increased when Bendazac is combined with Equilin. Experimental Bendroflumethiazide Equilin may increase the hypokalemic activities of Bendroflumethiazide. Approved Benorilate The risk or severity of adverse effects can be increased when Benorilate is combined with Equilin. Experimental Benoxaprofen The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Equilin. Withdrawn Benzoic Acid The therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Equilin. Approved Bevonium The risk or severity of adverse effects can be increased when Bevonium is combined with Equilin. Experimental Bismuth Subcitrate The bioavailability of Equilin can be decreased when combined with Bismuth Subcitrate. Approved Bismuth subnitrate The bioavailability of Equilin can be decreased when combined with Bismuth subnitrate. Experimental Boceprevir The serum concentration of Equilin can be increased when it is combined with Boceprevir. Withdrawn Bromfenac The risk or severity of adverse effects can be increased when Bromfenac is combined with Equilin. Approved Bucillamine The risk or severity of adverse effects can be increased when Bucillamine is combined with Equilin. Investigational Bufexamac The risk or severity of adverse effects can be increased when Bufexamac is combined with Equilin. Experimental Bumadizone The risk or severity of adverse effects can be increased when Bumadizone is combined with Equilin. Experimental Bumetanide Equilin may increase the hypokalemic activities of Bumetanide. Approved Calcitriol The therapeutic efficacy of Calcitriol can be decreased when used in combination with Equilin. Approved, Nutraceutical Calcium Carbonate The bioavailability of Equilin can be decreased when combined with Calcium Carbonate. Approved Calcium silicate The bioavailability of Equilin can be decreased when combined with Calcium silicate. Experimental Capromab pendetide Equilin may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Carbamazepine The serum concentration of Equilin can be decreased when it is combined with Carbamazepine. Approved, Investigational Carbaspirin calcium The risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Equilin. Experimental Carprofen The risk or severity of adverse effects can be increased when Carprofen is combined with Equilin. Approved, Vet Approved, Withdrawn Castanospermine The risk or severity of adverse effects can be increased when Castanospermine is combined with Equilin. Experimental Celecoxib The risk or severity of adverse effects can be increased when Celecoxib is combined with Equilin. Approved, Investigational Ceritinib Equilin may increase the hyperglycemic activities of Ceritinib. Approved Chloroquine The risk or severity of adverse effects can be increased when Chloroquine is combined with Equilin. Approved, Vet Approved Chlorothiazide Equilin may increase the hypokalemic activities of Chlorothiazide. Approved, Vet Approved Chlorotrianisene The serum concentration of Equilin can be increased when it is combined with Chlorotrianisene. Withdrawn Chlorthalidone Equilin may increase the hypokalemic activities of Chlorthalidone. Approved Cholestyramine Cholestyramine can cause a decrease in the absorption of Equilin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Choline magnesium trisalicylate The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Equilin. Approved Cinoxacin The risk or severity of adverse effects can be increased when Equilin is combined with Cinoxacin. Approved, Withdrawn Clarithromycin The serum concentration of Equilin can be increased when it is combined with Clarithromycin. Approved Clonixin The risk or severity of adverse effects can be increased when Clonixin is combined with Equilin. Approved Clostridium tetani toxoid antigen (formaldehyde inactivated) The risk or severity of adverse effects can be increased when Equilin is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated). Approved Cobicistat The serum concentration of Equilin can be increased when it is combined with Cobicistat. Approved Colesevelam Colesevelam can cause a decrease in the absorption of Equilin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Colestipol Colestipol can cause a decrease in the absorption of Equilin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Conjugated estrogens The serum concentration of Equilin can be increased when it is combined with Conjugated estrogens. Approved Corticorelin ovine triflutate The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Equilin. Approved Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) The risk or severity of adverse effects can be increased when Equilin is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated). Approved Coumaphos The risk or severity of adverse effects can be increased when Equilin is combined with Coumaphos. Vet Approved Curcumin The risk or severity of adverse effects can be increased when Curcumin is combined with Equilin. Investigational Cyclopenthiazide Equilin may increase the hypokalemic activities of Cyclopenthiazide. Experimental D-Limonene The risk or severity of adverse effects can be increased when D-Limonene is combined with Equilin. Investigational Daidzein The serum concentration of Equilin can be increased when it is combined with Daidzein. Experimental Darunavir The serum concentration of Equilin can be increased when it is combined with Darunavir. Approved Decamethonium The risk or severity of adverse effects can be increased when Equilin is combined with Decamethonium. Approved Deferasirox The risk or severity of adverse effects can be increased when Equilin is combined with Deferasirox. Approved, Investigational Demecarium The risk or severity of adverse effects can be increased when Equilin is combined with Demecarium. Approved dersalazine The risk or severity of adverse effects can be increased when dersalazine is combined with Equilin. Investigational Dichlorvos The risk or severity of adverse effects can be increased when Equilin is combined with Dichlorvos. Vet Approved Diclofenac The risk or severity of adverse effects can be increased when Diclofenac is combined with Equilin. Approved, Vet Approved Dienestrol The serum concentration of Equilin can be increased when it is combined with Dienestrol. Approved Diethylstilbestrol The serum concentration of Equilin can be increased when it is combined with Diethylstilbestrol. Approved Difenpiramide The risk or severity of adverse effects can be increased when Difenpiramide is combined with Equilin. Experimental Diflunisal The risk or severity of adverse effects can be increased when Diflunisal is combined with Equilin. Approved Dihydrotestosterone Equilin may increase the fluid retaining activities of Dihydrotestosterone. Illicit Distigmine The risk or severity of adverse effects can be increased when Equilin is combined with Distigmine. Experimental Donepezil The risk or severity of adverse effects can be increased when Equilin is combined with Donepezil. Approved Droxicam The risk or severity of adverse effects can be increased when Droxicam is combined with Equilin. Approved Duvelisib The risk or severity of adverse effects can be increased when Duvelisib is combined with Equilin. Investigational E-6201 The risk or severity of adverse effects can be increased when E-6201 is combined with Equilin. Investigational Echothiophate The risk or severity of adverse effects can be increased when Equilin is combined with Echothiophate. Approved Edrophonium The risk or severity of adverse effects can be increased when Equilin is combined with Edrophonium. Approved Enoxacin The risk or severity of adverse effects can be increased when Equilin is combined with Enoxacin. Approved Enzalutamide The serum concentration of Equilin can be decreased when it is combined with Enzalutamide. Approved Epimestrol The serum concentration of Equilin can be increased when it is combined with Epimestrol. Experimental Epirizole The risk or severity of adverse effects can be increased when Epirizole is combined with Equilin. Approved Equol The serum concentration of Equilin can be increased when it is combined with Equol. Investigational Estradiol The serum concentration of Equilin can be increased when it is combined with Estradiol. Approved, Investigational, Vet Approved Estriol The serum concentration of Equilin can be increased when it is combined with Estriol. Approved, Vet Approved Estrone The serum concentration of Equilin can be increased when it is combined with Estrone. Approved Etacrynic acid Equilin may increase the hypokalemic activities of Etacrynic acid. Approved Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Equilin. Approved, Investigational Ethenzamide The risk or severity of adverse effects can be increased when Ethenzamide is combined with Equilin. Experimental Ethinyl Estradiol The serum concentration of Equilin can be increased when it is combined with Ethinyl Estradiol. Approved Etodolac The risk or severity of adverse effects can be increased when Etodolac is combined with Equilin. Approved, Investigational, Vet Approved Etofenamate The risk or severity of adverse effects can be increased when Etofenamate is combined with Equilin. Approved Etoricoxib The risk or severity of adverse effects can be increased when Etoricoxib is combined with Equilin. Approved, Investigational Evening primrose oil The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Equilin. Approved exisulind The risk or severity of adverse effects can be increased when exisulind is combined with Equilin. Investigational Felbinac The risk or severity of adverse effects can be increased when Felbinac is combined with Equilin. Experimental Fenbufen The risk or severity of adverse effects can be increased when Fenbufen is combined with Equilin. Approved Fenoprofen The risk or severity of adverse effects can be increased when Fenoprofen is combined with Equilin. Approved Fenthion The risk or severity of adverse effects can be increased when Equilin is combined with Fenthion. Vet Approved Fentiazac The risk or severity of adverse effects can be increased when Fentiazac is combined with Equilin. Experimental Feprazone The risk or severity of adverse effects can be increased when Feprazone is combined with Equilin. Experimental Ferulic acid The risk or severity of adverse effects can be increased when Ferulic acid is combined with Equilin. Experimental Fleroxacin The risk or severity of adverse effects can be increased when Equilin is combined with Fleroxacin. Approved Floctafenine The risk or severity of adverse effects can be increased when Floctafenine is combined with Equilin. Approved, Withdrawn Flumequine The risk or severity of adverse effects can be increased when Equilin is combined with Flumequine. Withdrawn Flunixin The risk or severity of adverse effects can be increased when Flunixin is combined with Equilin. Vet Approved Flunoxaprofen The risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Equilin. Experimental Fluoxymesterone Equilin may increase the fluid retaining activities of Fluoxymesterone. Approved, Illicit Flurbiprofen The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Equilin. Approved, Investigational Fosaprepitant The serum concentration of Equilin can be increased when it is combined with Fosaprepitant. Approved Fosphenytoin The serum concentration of Equilin can be decreased when it is combined with Fosphenytoin. Approved Furosemide Equilin may increase the hypokalemic activities of Furosemide. Approved, Vet Approved G17DT The risk or severity of adverse effects can be increased when Equilin is combined with G17DT. Investigational Galantamine The risk or severity of adverse effects can be increased when Equilin is combined with Galantamine. Approved Gallamine Triethiodide The risk or severity of adverse effects can be increased when Equilin is combined with Gallamine Triethiodide. Approved Garenoxacin The risk or severity of adverse effects can be increased when Equilin is combined with Garenoxacin. Investigational Gatifloxacin The risk or severity of adverse effects can be increased when Equilin is combined with Gatifloxacin. Approved, Investigational Gemifloxacin The risk or severity of adverse effects can be increased when Equilin is combined with Gemifloxacin. Approved, Investigational Genistein The serum concentration of Equilin can be increased when it is combined with Genistein. Investigational GI-5005 The risk or severity of adverse effects can be increased when Equilin is combined with GI-5005. Investigational Ginkgo biloba The risk or severity of adverse effects can be increased when Equilin is combined with Ginkgo biloba. Approved, Nutraceutical GLPG-0492 Equilin may increase the fluid retaining activities of GLPG-0492. Investigational Glycerol Phenylbutyrate The therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Equilin. Approved Grepafloxacin The risk or severity of adverse effects can be increased when Equilin is combined with Grepafloxacin. Withdrawn Guacetisal The risk or severity of adverse effects can be increased when Guacetisal is combined with Equilin. Experimental Hemoglobin crosfumaril The risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Equilin. Experimental Hexestrol The serum concentration of Equilin can be increased when it is combined with Hexestrol. Withdrawn Higenamine The risk or severity of adverse effects can be increased when Higenamine is combined with Equilin. Investigational Huperzine A The risk or severity of adverse effects can be increased when Equilin is combined with Huperzine A. Investigational Hyaluronidase The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Equilin. Approved, Investigational Hydrochlorothiazide Equilin may increase the hypokalemic activities of Hydrochlorothiazide. Approved, Vet Approved Hydroflumethiazide Equilin may increase the hypokalemic activities of Hydroflumethiazide. Approved Hydrotalcite The bioavailability of Equilin can be decreased when combined with Hydrotalcite. Experimental Ibuprofen The risk or severity of adverse effects can be increased when Ibuprofen is combined with Equilin. Approved Ibuproxam The risk or severity of adverse effects can be increased when Ibuproxam is combined with Equilin. Withdrawn Icatibant The risk or severity of adverse effects can be increased when Icatibant is combined with Equilin. Approved Idelalisib The serum concentration of Equilin can be increased when it is combined with Idelalisib. Approved Imidazole salicylate The risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Equilin. Experimental Indacaterol Indacaterol may increase the hypokalemic activities of Equilin. Approved Indapamide Equilin may increase the hypokalemic activities of Indapamide. Approved Indinavir The serum concentration of Equilin can be increased when it is combined with Indinavir. Approved Indobufen The risk or severity of adverse effects can be increased when Indobufen is combined with Equilin. Investigational Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Equilin. Approved, Investigational Indoprofen The risk or severity of adverse effects can be increased when Indoprofen is combined with Equilin. Withdrawn INGN 201 The risk or severity of adverse effects can be increased when Equilin is combined with INGN 201. Investigational INGN 225 The risk or severity of adverse effects can be increased when Equilin is combined with INGN 225. Investigational Ipidacrine The risk or severity of adverse effects can be increased when Equilin is combined with Ipidacrine. Experimental Isoflurophate The risk or severity of adverse effects can be increased when Equilin is combined with Isoflurophate. Approved, Withdrawn Isoniazid The serum concentration of Isoniazid can be decreased when it is combined with Equilin. Approved Isoxicam The risk or severity of adverse effects can be increased when Isoxicam is combined with Equilin. Withdrawn Itraconazole The serum concentration of Equilin can be increased when it is combined with Itraconazole. Approved, Investigational Kebuzone The risk or severity of adverse effects can be increased when Kebuzone is combined with Equilin. Experimental Ketoconazole The serum concentration of Equilin can be increased when it is combined with Ketoconazole. Approved, Investigational Ketoprofen The risk or severity of adverse effects can be increased when Ketoprofen is combined with Equilin. Approved, Vet Approved Ketorolac The risk or severity of adverse effects can be increased when Ketorolac is combined with Equilin. Approved Leflunomide The risk or severity of adverse effects can be increased when Leflunomide is combined with Equilin. Approved, Investigational Levofloxacin The risk or severity of adverse effects can be increased when Equilin is combined with Levofloxacin. Approved, Investigational Lisofylline The risk or severity of adverse effects can be increased when Lisofylline is combined with Equilin. Investigational Lonazolac The risk or severity of adverse effects can be increased when Lonazolac is combined with Equilin. Experimental Lopinavir The serum concentration of Equilin can be increased when it is combined with Lopinavir. Approved Lornoxicam The risk or severity of adverse effects can be increased when Lornoxicam is combined with Equilin. Approved Loxoprofen The risk or severity of adverse effects can be increased when Loxoprofen is combined with Equilin. Approved Lumacaftor The serum concentration of Equilin can be decreased when it is combined with Lumacaftor. Approved Lumiracoxib The risk or severity of adverse effects can be increased when Lumiracoxib is combined with Equilin. Approved, Investigational Magaldrate The bioavailability of Equilin can be decreased when combined with Magaldrate. Withdrawn Magnesium Hydroxide The bioavailability of Equilin can be decreased when combined with Magnesium Hydroxide. Approved Magnesium oxide The bioavailability of Equilin can be decreased when combined with Magnesium oxide. Approved Magnesium peroxide The bioavailability of Equilin can be decreased when combined with Magnesium peroxide. Experimental Magnesium salicylate The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Equilin. Approved Magnesium silicate The bioavailability of Equilin can be decreased when combined with Magnesium silicate. Experimental Magnesium Trisilicate The bioavailability of Equilin can be decreased when combined with Magnesium Trisilicate. Approved Malathion The risk or severity of adverse effects can be increased when Equilin is combined with Malathion. Approved, Investigational Masoprocol The risk or severity of adverse effects can be increased when Masoprocol is combined with Equilin. Approved Meclofenamic acid The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Equilin. Approved, Vet Approved Mefenamic acid The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Equilin. Approved Mefloquine The risk or severity of adverse effects can be increased when Equilin is combined with Mefloquine. Approved Meloxicam The risk or severity of adverse effects can be increased when Meloxicam is combined with Equilin. Approved, Vet Approved Memantine The risk or severity of adverse effects can be increased when Equilin is combined with Memantine. Approved, Investigational Mesalazine The risk or severity of adverse effects can be increased when Mesalazine is combined with Equilin. Approved Mesterolone Equilin may increase the fluid retaining activities of Mesterolone. Experimental Mestranol The serum concentration of Equilin can be increased when it is combined with Mestranol. Approved Metamizole The risk or severity of adverse effects can be increased when Metamizole is combined with Equilin. Withdrawn Methallenestril The serum concentration of Equilin can be increased when it is combined with Methallenestril. Experimental Methanesulfonyl Fluoride The risk or severity of adverse effects can be increased when Equilin is combined with Methanesulfonyl Fluoride. Investigational Methyclothiazide Equilin may increase the hypokalemic activities of Methyclothiazide. Approved Methyl salicylate The risk or severity of adverse effects can be increased when Equilin is combined with Methyl salicylate. Approved, Vet Approved Methyltestosterone Equilin may increase the fluid retaining activities of Methyltestosterone. Approved Metoclopramide The risk or severity of adverse effects can be increased when Equilin is combined with Metoclopramide. Approved, Investigational Metolazone Equilin may increase the hypokalemic activities of Metolazone. Approved Mifepristone The therapeutic efficacy of Equilin can be decreased when used in combination with Mifepristone. Approved, Investigational Minaprine The risk or severity of adverse effects can be increased when Equilin is combined with Minaprine. Approved Mitotane The serum concentration of Equilin can be decreased when it is combined with Mitotane. Approved Mivacurium Mivacurium may increase the adverse neuromuscular activities of Equilin. Approved Mizoribine The risk or severity of adverse effects can be increased when Mizoribine is combined with Equilin. Investigational Mofebutazone The risk or severity of adverse effects can be increased when Mofebutazone is combined with Equilin. Experimental Moxestrol The serum concentration of Equilin can be increased when it is combined with Moxestrol. Experimental Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Equilin. Approved, Investigational Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Equilin. Approved Nabumetone The risk or severity of adverse effects can be increased when Nabumetone is combined with Equilin. Approved Nafamostat The risk or severity of adverse effects can be increased when Nafamostat is combined with Equilin. Approved, Investigational Naftifine The risk or severity of adverse effects can be increased when Naftifine is combined with Equilin. Approved Nalidixic Acid The risk or severity of adverse effects can be increased when Equilin is combined with Nalidixic Acid. Approved Nandrolone Equilin may increase the fluid retaining activities of Nandrolone. Experimental Naproxen The risk or severity of adverse effects can be increased when Naproxen is combined with Equilin. Approved, Vet Approved Nefazodone The serum concentration of Equilin can be increased when it is combined with Nefazodone. Approved, Withdrawn Nelfinavir The serum concentration of Equilin can be increased when it is combined with Nelfinavir. Approved Nemonoxacin The risk or severity of adverse effects can be increased when Equilin is combined with Nemonoxacin. Investigational Neostigmine The risk or severity of adverse effects can be increased when Equilin is combined with Neostigmine. Approved, Vet Approved Nepafenac The risk or severity of adverse effects can be increased when Nepafenac is combined with Equilin. Approved Nevirapine The serum concentration of Equilin can be decreased when it is combined with Nevirapine. Approved Nicorandil The risk or severity of adverse effects can be increased when Equilin is combined with Nicorandil. Approved Nifenazone The risk or severity of adverse effects can be increased when Nifenazone is combined with Equilin. Experimental Niflumic Acid The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Equilin. Approved Nimesulide The risk or severity of adverse effects can be increased when Nimesulide is combined with Equilin. Approved, Withdrawn Nitroaspirin The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Equilin. Investigational Norfloxacin The risk or severity of adverse effects can be increased when Equilin is combined with Norfloxacin. Approved Olopatadine The risk or severity of adverse effects can be increased when Olopatadine is combined with Equilin. Approved Olsalazine The risk or severity of adverse effects can be increased when Olsalazine is combined with Equilin. Approved Orgotein The risk or severity of adverse effects can be increased when Orgotein is combined with Equilin. Vet Approved Oxandrolone Equilin may increase the fluid retaining activities of Oxandrolone. Approved, Investigational Oxaprozin The risk or severity of adverse effects can be increased when Oxaprozin is combined with Equilin. Approved Oxolinic acid The risk or severity of adverse effects can be increased when Equilin is combined with Oxolinic acid. Experimental Oxymetholone Equilin may increase the fluid retaining activities of Oxymetholone. Approved, Illicit Oxyphenbutazone The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Equilin. Withdrawn Paraoxon The risk or severity of adverse effects can be increased when Equilin is combined with Paraoxon. Experimental Parecoxib The risk or severity of adverse effects can be increased when Parecoxib is combined with Equilin. Approved Parthenolide The risk or severity of adverse effects can be increased when Parthenolide is combined with Equilin. Investigational Pazufloxacin The risk or severity of adverse effects can be increased when Equilin is combined with Pazufloxacin. Investigational Pefloxacin The risk or severity of adverse effects can be increased when Equilin is combined with Pefloxacin. Approved Pentobarbital The serum concentration of Equilin can be decreased when it is combined with Pentobarbital. Approved, Vet Approved Phenobarbital The serum concentration of Equilin can be decreased when it is combined with Phenobarbital. Approved Phenylacetic acid The therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Equilin. Approved Phenylbutazone The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Equilin. Approved, Vet Approved Phenylbutyric acid The therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Equilin. Approved, Investigational Phenytoin The serum concentration of Equilin can be decreased when it is combined with Phenytoin. Approved, Vet Approved Physostigmine The risk or severity of adverse effects can be increased when Equilin is combined with Physostigmine. Approved Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Equilin. Approved, Investigational Pipemidic acid The risk or severity of adverse effects can be increased when Equilin is combined with Pipemidic acid. Experimental Piretanide Equilin may increase the hypokalemic activities of Piretanide. Experimental Pirfenidone The risk or severity of adverse effects can be increased when Pirfenidone is combined with Equilin. Investigational Piromidic acid The risk or severity of adverse effects can be increased when Equilin is combined with Piromidic acid. Experimental Piroxicam The risk or severity of adverse effects can be increased when Piroxicam is combined with Equilin. Approved, Investigational Pirprofen The risk or severity of adverse effects can be increased when Pirprofen is combined with Equilin. Experimental Polyestradiol phosphate The serum concentration of Equilin can be increased when it is combined with Polyestradiol phosphate. Approved Polythiazide Equilin may increase the hypokalemic activities of Polythiazide. Approved Posaconazole The serum concentration of Equilin can be increased when it is combined with Posaconazole. Approved, Investigational, Vet Approved Pranoprofen The risk or severity of adverse effects can be increased when Pranoprofen is combined with Equilin. Experimental Primidone The serum concentration of Equilin can be decreased when it is combined with Primidone. Approved, Vet Approved Proglumetacin The risk or severity of adverse effects can be increased when Proglumetacin is combined with Equilin. Experimental Promestriene The serum concentration of Equilin can be increased when it is combined with Promestriene. Investigational Propacetamol The risk or severity of adverse effects can be increased when Propacetamol is combined with Equilin. Approved Propyphenazone The risk or severity of adverse effects can be increased when Propyphenazone is combined with Equilin. Experimental Proquazone The risk or severity of adverse effects can be increased when Proquazone is combined with Equilin. Experimental Prulifloxacin The risk or severity of adverse effects can be increased when Equilin is combined with Prulifloxacin. Investigational PTC299 The risk or severity of adverse effects can be increased when PTC299 is combined with Equilin. Investigational Pyridostigmine The risk or severity of adverse effects can be increased when Equilin is combined with Pyridostigmine. Approved Quinestrol The serum concentration of Equilin can be increased when it is combined with Quinestrol. Approved Quinethazone Equilin may increase the hypokalemic activities of Quinethazone. Approved Rabies virus inactivated antigen, A The risk or severity of adverse effects can be increased when Equilin is combined with Rabies virus inactivated antigen, A. Approved Rapacuronium Rapacuronium may increase the adverse neuromuscular activities of Equilin. Withdrawn Resveratrol The risk or severity of adverse effects can be increased when Resveratrol is combined with Equilin. Experimental, Investigational Rifabutin The serum concentration of Equilin can be decreased when it is combined with Rifabutin. Approved Rifampicin The serum concentration of Equilin can be decreased when it is combined with Rifampicin. Approved Rifapentine The serum concentration of Equilin can be decreased when it is combined with Rifapentine. Approved Rindopepimut The risk or severity of adverse effects can be increased when Equilin is combined with Rindopepimut. Investigational Ritonavir The serum concentration of Equilin can be increased when it is combined with Ritonavir. Approved, Investigational Rivastigmine The risk or severity of adverse effects can be increased when Equilin is combined with Rivastigmine. Approved, Investigational Rofecoxib The risk or severity of adverse effects can be increased when Rofecoxib is combined with Equilin. Investigational, Withdrawn Rosoxacin The risk or severity of adverse effects can be increased when Equilin is combined with Rosoxacin. Approved Rotavirus Vaccine The risk or severity of adverse effects can be increased when Equilin is combined with Rotavirus Vaccine. Approved Rubella virus vaccine The risk or severity of adverse effects can be increased when Equilin is combined with Rubella virus vaccine. Approved Rufloxacin The risk or severity of adverse effects can be increased when Equilin is combined with Rufloxacin. Experimental Salicylamide The risk or severity of adverse effects can be increased when Salicylamide is combined with Equilin. Approved Salicylic acid The risk or severity of adverse effects can be increased when Salicylic acid is combined with Equilin. Approved, Vet Approved Salsalate The risk or severity of adverse effects can be increased when Salsalate is combined with Equilin. Approved Saquinavir The serum concentration of Equilin can be increased when it is combined with Saquinavir. Approved, Investigational Secoisolariciresinol The serum concentration of Equilin can be increased when it is combined with Secoisolariciresinol. Investigational Semapimod The risk or severity of adverse effects can be increased when Semapimod is combined with Equilin. Investigational Seratrodast The risk or severity of adverse effects can be increased when Seratrodast is combined with Equilin. Approved Serrapeptase The risk or severity of adverse effects can be increased when Serrapeptase is combined with Equilin. Investigational Sitafloxacin The risk or severity of adverse effects can be increased when Equilin is combined with Sitafloxacin. Experimental Sparfloxacin The risk or severity of adverse effects can be increased when Equilin is combined with Sparfloxacin. Approved SRP 299 The risk or severity of adverse effects can be increased when Equilin is combined with SRP 299. Investigational SRT501 The risk or severity of adverse effects can be increased when SRT501 is combined with Equilin. Investigational St. John's Wort The serum concentration of Equilin can be decreased when it is combined with St. John's Wort. Nutraceutical Stanozolol Equilin may increase the fluid retaining activities of Stanozolol. Approved, Vet Approved Stiripentol The serum concentration of Equilin can be increased when it is combined with Stiripentol. Approved Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Equilin. Approved Sulindac The risk or severity of adverse effects can be increased when Sulindac is combined with Equilin. Approved Suprofen The risk or severity of adverse effects can be increased when Suprofen is combined with Equilin. Approved, Withdrawn Suxibuzone The risk or severity of adverse effects can be increased when Suxibuzone is combined with Equilin. Experimental Synthetic Conjugated Estrogens, A The serum concentration of Equilin can be increased when it is combined with Synthetic Conjugated Estrogens, A. Approved Synthetic Conjugated Estrogens, B The serum concentration of Equilin can be increased when it is combined with Synthetic Conjugated Estrogens, B. Approved Tacrine The risk or severity of adverse effects can be increased when Equilin is combined with Tacrine. Withdrawn Tarenflurbil The risk or severity of adverse effects can be increased when Tarenflurbil is combined with Equilin. Investigational Tecemotide The risk or severity of adverse effects can be increased when Equilin is combined with Tecemotide. Investigational Telaprevir The serum concentration of Telaprevir can be decreased when it is combined with Equilin. Withdrawn Telithromycin The serum concentration of Equilin can be increased when it is combined with Telithromycin. Approved Temafloxacin The risk or severity of adverse effects can be increased when Equilin is combined with Temafloxacin. Withdrawn Tenidap The risk or severity of adverse effects can be increased when Tenidap is combined with Equilin. Experimental Tenoxicam The risk or severity of adverse effects can be increased when Tenoxicam is combined with Equilin. Approved Tepoxalin The risk or severity of adverse effects can be increased when Tepoxalin is combined with Equilin. Vet Approved Teriflunomide The risk or severity of adverse effects can be increased when Teriflunomide is combined with Equilin. Approved Testosterone Equilin may increase the fluid retaining activities of Testosterone. Approved, Investigational TG4010 The risk or severity of adverse effects can be increased when Equilin is combined with TG4010. Investigational Tiaprofenic acid The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Equilin. Approved Tibolone The serum concentration of Equilin can be increased when it is combined with Tibolone. Approved Tinoridine The risk or severity of adverse effects can be increased when Tinoridine is combined with Equilin. Investigational Tolfenamic Acid The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Equilin. Approved Tolmetin The risk or severity of adverse effects can be increased when Tolmetin is combined with Equilin. Approved Torasemide Equilin may increase the hypokalemic activities of Torasemide. Approved Tranilast The risk or severity of adverse effects can be increased when Tranilast is combined with Equilin. Approved, Investigational Tribenoside The risk or severity of adverse effects can be increased when Tribenoside is combined with Equilin. Experimental Trichlorfon The risk or severity of adverse effects can be increased when Equilin is combined with Trichlorfon. Vet Approved Trichlormethiazide Equilin may increase the hypokalemic activities of Trichlormethiazide. Approved, Vet Approved Triptolide The risk or severity of adverse effects can be increased when Triptolide is combined with Equilin. Investigational Trovafloxacin The risk or severity of adverse effects can be increased when Equilin is combined with Trovafloxacin. Approved, Withdrawn Tubocurarine The risk or severity of adverse effects can be increased when Equilin is combined with Tubocurarine. Approved Valdecoxib The risk or severity of adverse effects can be increased when Valdecoxib is combined with Equilin. Investigational, Withdrawn Voriconazole The serum concentration of Equilin can be increased when it is combined with Voriconazole. Approved, Investigational Warfarin Equilin may increase the anticoagulant activities of Warfarin. Approved Yellow fever vaccine The risk or severity of adverse effects can be increased when Equilin is combined with Yellow fever vaccine. Approved Zaltoprofen The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Equilin. Approved Zeranol The serum concentration of Equilin can be increased when it is combined with Zeranol. Vet Approved Zileuton The risk or severity of adverse effects can be increased when Zileuton is combined with Equilin. Approved, Investigational, Withdrawn Zomepirac The risk or severity of adverse effects can be increased when Zomepirac is combined with Equilin. Withdrawn Zoster vaccine The risk or severity of adverse effects can be increased when Equilin is combined with Zoster vaccine. Approved - Food Interactions
- Not Available
References
- General References
- Sawicki MW, Erman M, Puranen T, Vihko P, Ghosh D: Structure of the ternary complex of human 17beta-hydroxysteroid dehydrogenase type 1 with 3-hydroxyestra-1,3,5,7-tetraen-17-one (equilin) and NADP+. Proc Natl Acad Sci U S A. 1999 Feb 2;96(3):840-5. [PubMed:9927655]
- External Links
- PDB Entries
- 1equ
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 239 °C PhysProp water solubility 1.41 mg/L (at 25 °C) YALKOWSKY,SH & DANNENFELSER,RM (1992) - Predicted Properties
Property Value Source Water Solubility 0.0133 mg/mL ALOGPS logP 3.8 ALOGPS logP 3.9 ChemAxon logS -4.3 ALOGPS pKa (Strongest Acidic) 9.41 ChemAxon pKa (Strongest Basic) -6 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 37.3 Å2 ChemAxon Rotatable Bond Count 0 ChemAxon Refractivity 79.93 m3·mol-1 ChemAxon Polarizability 30.55 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9192 Caco-2 permeable + 0.875 P-glycoprotein substrate Substrate 0.6807 P-glycoprotein inhibitor I Non-inhibitor 0.8085 P-glycoprotein inhibitor II Non-inhibitor 0.8881 Renal organic cation transporter Non-inhibitor 0.6704 CYP450 2C9 substrate Non-substrate 0.7245 CYP450 2D6 substrate Non-substrate 0.9081 CYP450 3A4 substrate Substrate 0.7666 CYP450 1A2 substrate Inhibitor 0.9108 CYP450 2C9 inhibitor Non-inhibitor 0.9071 CYP450 2D6 inhibitor Non-inhibitor 0.9231 CYP450 2C19 inhibitor Inhibitor 0.8209 CYP450 3A4 inhibitor Non-inhibitor 0.8156 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.5528 Ames test Non AMES toxic 0.9109 Carcinogenicity Non-carcinogens 0.93 Biodegradation Not ready biodegradable 0.9319 Rat acute toxicity 1.8021 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.7619 hERG inhibition (predictor II) Non-inhibitor 0.601
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Mass Spectrum (Electron Ionization) MS splash10-014i-3940000000-b80393e552aa78600070 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available 13C NMR Spectrum 1D NMR Not Applicable
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as oxosteroids. These are steroid derivatives carrying a C=O group attached to steroid skeleton.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Steroids and steroid derivatives
- Sub Class
- Oxosteroids
- Direct Parent
- Oxosteroids
- Alternative Parents
- 3-hydroxy delta-7-steroids / 17-oxosteroids / Delta-7-steroids / Phenanthrenes and derivatives / Naphthalenes / 1-hydroxy-2-unsubstituted benzenoids / Ketones / Organic oxides / Hydrocarbon derivatives
- Substituents
- 3-hydroxy-delta-7-steroid / 3-hydroxysteroid / Hydroxysteroid / Oxosteroid / 17-oxosteroid / Delta-7-steroid / Phenanthrene / Naphthalene / 1-hydroxy-2-unsubstituted benzenoid / Benzenoid
- Molecular Framework
- Aromatic homopolycyclic compounds
- External Descriptors
- 17-oxo steroid, 3-hydroxy steroid (CHEBI:42309) / Estrane and derivatives (C14392) / C18 steroids (estrogens) and derivatives (LMST02010026)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Testosterone dehydrogenase (nad+) activity
- Specific Function
- Favors the reduction of estrogens and androgens. Also has 20-alpha-HSD activity. Uses preferentially NADH.
- Gene Name
- HSD17B1
- Uniprot ID
- P14061
- Uniprot Name
- Estradiol 17-beta-dehydrogenase 1
- Molecular Weight
- 34949.715 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Zinc ion binding
- Specific Function
- Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissu...
- Gene Name
- ESR1
- Uniprot ID
- P03372
- Uniprot Name
- Estrogen receptor
- Molecular Weight
- 66215.45 Da
References
- Starcevic S, Brozic P, Turk S, Cesar J, Rizner TL, Gobec S: Synthesis and biological evaluation of (6- and 7-phenyl) coumarin derivatives as selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2011 Jan 13;54(1):248-61. doi: 10.1021/jm101104z. Epub 2010 Dec 7. [PubMed:21138273]
Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 05:07